Veratis Advisors’s AbbVie ABBV Stock Holding History

Veratis Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$238K	Buy	+947	New	+$204K	0.17%	76
2025 Q4	$218K	Buy	+938	New	+$214K	0.17%	74

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Veratis Advisors's ABBV Position: Q2 2026 in Review

Veratis Advisors opened a new position in AbbVie (ABBV) in Q2 2026: 947 shares worth $238K. The stake represents 0.17% of the portfolio and ranks #76 among its holdings. This is a return to the name: Veratis Advisors previously reported a position in ABBV as recently as Q4 2025.

Veratis Advisors first reported a position in ABBV in Q4 2025 and has held it in 2 quarters since. 4,207 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Veratis Advisors held 947 shares of AbbVie worth $238K as of Q2 2026.
AbbVie was a new Veratis Advisors position in Q2 2026.
AbbVie made up 0.17% of Veratis Advisors's portfolio in Q2 2026, its #76 holding.
Veratis Advisors first reported a position in AbbVie in Q4 2025 and has held it in 2 quarters since.
4,207 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Veratis Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.